University of Ioannina
Επίδραση του συνδυασμού στατίνης με ανταγωνιστή των υποδοχέων της αγγειοτενσίνης II σε ασθενείς με υπέρταση, μικτή δυσλιπιδαιμία και διαταραχή γλυκόζης νηστείας
Abstract
dc:descriptionIntroduction: The presence of multiple risk factors is one of the major problems in everyday clinical practice multiplying the risk of cardiovascular disease. Good clinical practice requires a comprehensive and aggressive treatment of patients with multiple risk factors. In this effort, it is of great importance to identify effective drug combinations. Statins are the basis of lipid lowering therapy as they have demonstrated their effectiveness and safety. Angiotensin II receptor blockers, are commonly used antihypertensive drugs which are effective and well tolerated. Their beneficial effects have been associated with the blockade of AT1 receptors of angiotensin II as well as other favorable effects such as the improvement of insulin sensitivity. Telmisartan, and to a lesser extent irbesartan, activate the peroxisome proliferator-activated receptor γ (PPARγ) altering the expression of genes that affect the metabolism of lipids and carbohydrates. It is not clear whether the co-administration of these drugs with statins can lead to significant improvement of metabolic parameters beyond their expected antihypertensive effect.Objective: To evaluate the effects of combining rosuvastatin with ARBs of varying PPARγ activating potency in patients with hypertension, mixed dyslipidemia, and impaired fasting glucose on various metabolic parameters.Methods: The study enrolled 151 patients with hypertension, mixed dyslipidemia, and impaired fasting glucose who received dietary advice and were randomized to receive rosuvastatin 10 mg/day together with: a) telmisartan (80 mg/day; n=52) or b) irbesartan (150 mg/day; n=48) or c), olmesartan (20 mg/day; n=51). The anthropometric and metabolic parameters were assessed at baseline and after 6 months of treatment.Results: After study end, anthropometric parameters (body weight, BMI, waist circumference) were not significantly altered in any of the 3 groups. Moreover, the reduction of systolic and diastolic blood pressure was similar in all groups. In the telmisartan group, a significant decrease was observed of insulin resistance index (HOMA-IR) (-29%) compared with baseline and other groups (p <0.05). Lipid profile was similarly altered in all groups. Cholesterol of LDL subfractions as well as the activity and mass of plasma Lp-PLA2 were reduced similarly in all study subjects. Cholesterol of large HDL subfractions increased significantly in contrast to small HDL subfractions which were significantly decreased. The activity of HDL-Lp-PLA2 increased significantly only in the telmisartan group (+ 21%, p <0.01) in contrast to the other two groups in which it remained unchanged (p <0.01 for the comparison between groups). The mass of HDL-Lp-PLA2 and the activities of PON1 to paraoxon and phenylacetate were unchanged in all groups. Both levels of 8-iso-PGF2a (-8.6%, p=0.02) and hsCRP (-44%, p<0.05) significantly decreased only in the telmisartan group. Renal function parameters and levels of liver function tests were not significantly altered in any group.Conclusions: In hypertensive patients with mixed dyslipidemia and impaired fasting glucose, concomitant use of rosuvastatin with telmisartan is associated with a beneficial effect on glycemic profile and various metabolic parameters, which are predictors of cardiovascular disease occurrence.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Rizos, Christos
- Ρίζος, Χρήστος
Subjects
dc:subject × 18- Υπέρταση
- Δυσλιπιδαιμία
- Διαταραχή γλυκόζης νηστείας
- Στατίνες
- Ανταγωνιστές των υποδοχέων της αγγειοτενσίνης ΙΙ
- Πυρηνικοί υποδοχείς PPARγ
- Hypertension
- Dyslipidemia
- Impaired fasting glucose
- Statins
- Angiotensin receptor blockers
- PPARγ nuclear receptors
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44349